{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:17:39Z","timestamp":1769008659466,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,20]],"date-time":"2020-09-20T00:00:00Z","timestamp":1600560000000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI150461"],"award-info":[{"award-number":["AI150461"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI150466"],"award-info":[{"award-number":["AI150466"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006224","name":"Argonne National Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006389","name":"Advanced Photon Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006389","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bbrc.2019.08.126","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T17:14:48Z","timestamp":1567098888000},"page":"61-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20"],"prefix":"10.1016","volume":"519","author":[{"given":"Daniel W.","family":"Kneller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnson","family":"Agniswamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-7393","authenticated-orcid":false,"given":"Irene T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2019.08.126_bib1","author":"UNAIDS"},{"key":"10.1016\/j.bbrc.2019.08.126_bib2","author":"WHO"},{"key":"10.1016\/j.bbrc.2019.08.126_bib3","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix089","article-title":"Impact of HIV drug resistance on HIV\/AIDS-Associated mortality, new infections, and antiretroviral therapy program costs in sub\u2013saharan Africa","volume":"215","author":"Phillips","year":"2017","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.bbrc.2019.08.126_bib4","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1128\/AAC.47.10.3123-3129.2003","article-title":"Novel bis-Tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in\u00a0vitro","volume":"47","author":"Koh","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2019.08.126_bib5","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"10.1016\/j.bbrc.2019.08.126_bib6","first-page":"196","article-title":"HIV-1 resistance rarely observed in subjects using darunavir once-daily regimens across clinical studies, HIV","volume":"18","author":"Lathouwers","year":"2017","journal-title":"Clin. Trials"},{"key":"10.1016\/j.bbrc.2019.08.126_bib7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1468-1293.2012.01060.x","article-title":"Final 192-week efficacy and safety of once-daily darunavir\/ritonavir compared with lopinavir\/ritonavir in HIV-1-infected treatment-na\u00efve patients in the ARTEMIS trial","volume":"14","author":"Orkin","year":"2013","journal-title":"HIV Med."},{"key":"10.1016\/j.bbrc.2019.08.126_bib8","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1102278108","article-title":"Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors","volume":"108","author":"Louis","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.bbrc.2019.08.126_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-6405-7-27","article-title":"Autoprocessing of human immunodeficiency virus type 1 protease miniprecursor fusions in mammalian cells","volume":"7","author":"Huang","year":"2010","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.bbrc.2019.08.126_bib10","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1021\/ct300032r","article-title":"How does darunavir prevent HIV-1 protease dimerization?","volume":"8","author":"Huang","year":"2012","journal-title":"J.\u00a0Chem. Theory Comput."},{"key":"10.1016\/j.bbrc.2019.08.126_bib11","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1093\/infdis\/jix137","article-title":"Global HIV antiretroviral drug resistance","volume":"216","author":"Godfrey","year":"2017","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.bbrc.2019.08.126_bib12","first-page":"132","article-title":"2017 update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2017","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.bbrc.2019.08.126_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.4155\/fmc.15.44","article-title":"Highly resistant HIV-1 proteases and strategies for their inhibition","volume":"7","author":"Weber","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bbrc.2019.08.126_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168616","article-title":"Structural studies of a rationally selected multi-drug resistant HIV-1 protease reveal synergistic effect of distal mutations on flap dynamics","volume":"11","author":"Agniswamy","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2019.08.126_bib15","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/acs.biochem.6b00012","article-title":"Binding of clinical inhibitors to a model precursor of a rationally selected multidrug resistant HIV-1 protease is significantly weaker than that to the released mature enzyme","volume":"55","author":"Park","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2019.08.126_bib16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1107\/S0907444911011541","article-title":"Contribution of the 80s loop of HIV-1 protease to the multidrug-resistance mechanism: crystallographic study of MDR769 HIV-1 protease variants","volume":"67","author":"Yedidi","year":"2011","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2019.08.126_bib17","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1128\/AAC.00465-12","article-title":"Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease","volume":"56","author":"Koz\u00edsek","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2019.08.126_bib18","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/bi2018317","article-title":"HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements","volume":"51","author":"Agniswamy","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2019.08.126_bib19","doi-asserted-by":"crossref","first-page":"13845","DOI":"10.1128\/JVI.01184-07","article-title":"Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier","volume":"81","author":"Dierynck","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.bbrc.2019.08.126_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jmgm.2015.09.006","article-title":"Conformational variation of an extreme drug resistant mutant of HIV protease","volume":"62","author":"Shen","year":"2015","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"10.1016\/j.bbrc.2019.08.126_bib21","doi-asserted-by":"crossref","first-page":"11607","DOI":"10.1039\/C5OB01930C","article-title":"Design, synthesis, biological evaluation and X-ray structural studies of HIV-1 protease inhibitors containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligands","volume":"13","author":"Ghosh","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bbrc.2019.08.126_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/07391102.2015.1018326","article-title":"Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights","volume":"34","author":"Chetty","year":"2016","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2019.08.126_bib23","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1021\/bi400962r","article-title":"Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease","volume":"52","author":"Louis","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbrc.2019.08.126_bib24","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1021\/jm400231v","article-title":"Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1\u2019-pyrrolidinone or P2-tris-tetrahydrofuran","volume":"56","author":"Agniswamy","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2019.08.126_bib25","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1021\/acs.jmedchem.5b00474","article-title":"Substituted bis-THF protease inhibitors with improved potency against highly resistant mature HIV-1 protease PR20","volume":"58","author":"Agniswamy","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2019.08.126_bib26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40265-016-0678-9","article-title":"Treating HIV infection in the central nervous system","volume":"77","author":"Calcagno","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2019.08.126_bib27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cmdc.201700824","article-title":"Design of highly potent, dual-acting and central-nervous-system-penetrating HIV-1 protease inhibitors with excellent potency against multidrug-resistant HIV-1 variants","volume":"13","author":"Ghosh","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbrc.2019.08.126_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.28020","article-title":"A\u00a0novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency","volume":"6","author":"Aoki","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.bbrc.2019.08.126_bib29","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.7b00172","article-title":"Design and development of highly potent HIV-1 protease inhibitors with a crown-like oxotricyclic core as the P2-ligand to combat multidrug-resistant HIV variants","author":"Ghosh","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.bbrc.2019.08.126_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02635-18","article-title":"Halogen bond interactions of novel HIV-1 protease inhibitors (PI)(GRL-001-15 and GRL-003-15) with the flap of protease are critical for their potent activity against wild-type and multi-PI-resistant HIV-1 variants","author":"Hattori","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2019.08.126_bib31","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1128\/AAC.01420-13","article-title":"GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in\u00a0vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration","volume":"57","author":"Salcedo G\u00f3mez","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2019.08.126_bib32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cmdc.201402358","article-title":"Design of gem -difluoro- bis -tetrahydrofuran as P2 ligand for HIV-1 Protease inhibitors to improve brain penetration: synthesis, X-ray studies, and biological evaluation","volume":"10","author":"Ghosh","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bbrc.2019.08.126_bib33","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1021\/acsomega.9b00683","article-title":"Highly drug-resistant HIV-1 protease mutant PRS17 shows enhanced binding to substrate analogues","volume":"4","author":"Agniswamy","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.bbrc.2019.08.126_bib34","series-title":"Processing of X-Ray Diffraction Data Collected in Oscillation Mode","author":"Otwinowski","year":"1997"},{"key":"10.1016\/j.bbrc.2019.08.126_bib35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J.\u00a0Appl. Crystallogr."},{"key":"10.1016\/j.bbrc.2019.08.126_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2019.08.126_bib37","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2019.08.126_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2019.08.126_bib39","first-page":"82","article-title":"Pymol: an open-source molecular graphics tool","volume":"40","author":"DeLano","year":"2002","journal-title":"CCP4 Newsl. Protein Crystallogr."},{"key":"10.1016\/j.bbrc.2019.08.126_bib40","doi-asserted-by":"crossref","first-page":"12012","DOI":"10.1128\/JVI.78.21.12012-12021.2004","article-title":"Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor","volume":"78","author":"King","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.bbrc.2019.08.126_bib41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1747-0285.2008.00647.x","article-title":"Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use","volume":"71","author":"Brower","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.bbrc.2019.08.126_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/aid.2010.0072","article-title":"The HIV type 1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors","volume":"27","author":"Flor-Parra","year":"2011","journal-title":"AIDS Res. Hum. Retrovir."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X19316559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X19316559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:35:56Z","timestamp":1762094156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X19316559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0006291X19316559"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.08.126","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.08.126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}